Osimertinib

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Conditions

EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Trial Timeline

May 30, 2018 → Sep 19, 2023

NCT ID

NCT03239340

About Osimertinib

Osimertinib is a phase 2 stage product being developed by AstraZeneca for EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03239340. Target conditions include EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07295821	Phase 2	Recruiting	Mar 9, 2026	May 30, 2029	Lung Cancer
NCT05629234	Phase 3	Active	May 8, 2023	Feb 22, 2027	Cancer
NCT05546866	Phase 2	Active	Feb 9, 2023	Jun 30, 2029	Non-small Cell Lung Cancer
NCT04908956	Phase 2	Terminated	Aug 4, 2022	Feb 29, 2024	NSCLC Stage IV
NCT05089916	Phase 2	Active	Jan 20, 2022	Mar 1, 2027	NSCLC
NCT05215951	Phase 2	Terminated	Jan 19, 2022	Mar 9, 2023	Lung Cancer
NCT05103605	Pre-clinical	Active	May 12, 2021	Jan 15, 2026	Non Small Cell Lung Cancer
NCT05421936	Pre-clinical	Active	Sep 27, 2020	Sep 1, 2024	Carcinoma, Non-Small-Cell Lung
NCT04391283	Pre-clinical	UNKNOWN	Jul 27, 2020	Dec 1, 2024	Carcinoma, Non-Small-Cell Lung
NCT03853551	Approved	Completed	Apr 18, 2019	Apr 15, 2020	Non Small Cell Lung Cancer (NSCLC)
NCT03769103	Phase 2	Active	Mar 19, 2019	Apr 1, 2025	Lung Cancer Non-small Cell Stage IV
NCT03732352	Phase 2	Completed	Nov 28, 2018	Jan 31, 2024	EGFR Gene Amplification
NCT03667820	Phase 2	Active	Sep 26, 2018	Sep 30, 2027	Non-small Cell Lung Cancer (NSCLC)
NCT03586453	Phase 2	Recruiting	Aug 13, 2018	Mar 1, 2027	Carcinoma, Non-Small-Cell Lung
NCT03433469	Phase 2	Active	Jul 31, 2018	Oct 31, 2026	Stage I Non-Small Cell Lung Cancer
NCT03239340	Phase 2	Completed	May 30, 2018	Sep 19, 2023	EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT03219970	Pre-clinical	Completed	Sep 5, 2017	Oct 28, 2020	Non-small Cell Lung Cancer
NCT03394118	Phase 2	Completed	Aug 11, 2017	Apr 8, 2021	NSCLC
NCT03133234	Pre-clinical	Completed	May 23, 2017	Sep 13, 2017	T790M Positive NSCLC Patients
NCT02841579	Phase 2	Completed	Sep 2, 2016	Feb 14, 2020	Non-Small Cell Lung Cancer

Competing Products

20 competing products in EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

See all competitors

Product	Company	Stage	Hype Score
YH25448	Yuhan	Phase 1/2	41
YH32364	Yuhan	Phase 1/2	41
Datopotamab deruxtecan	Daiichi Sankyo	Pre-clinical	23
HER3-DXd	Daiichi Sankyo	Pre-clinical	23
ASP8273	Astellas Pharma	Phase 2	52
radio-labeled naquotinib + naquotinib	Astellas Pharma	Phase 1	33
erlotinib	Astellas Pharma	Phase 1	33
ASP8273 Capsules + ASP8273 Capsules A	Astellas Pharma	Phase 2	52
famitinib po + HS-10296 po	Jiangsu Hengrui Medicine	Phase 2	52
ABT-414	AbbVie	Pre-clinical	23
AZD9291 40 mg + AZD9291 80 mg	AstraZeneca	Phase 1	33
Osimertinib-based adaptive treatment + Osimertinib 80 MG	AstraZeneca	Phase 2	52
AZD9291 + MEDI4736	AstraZeneca	Phase 3	77
EGFR TKIs (gefitinib, erlotinib, afatinib, et al)	AstraZeneca	Pre-clinical	23
AZD9291	AstraZeneca	Pre-clinical	23
Dasatinib + Osimertinib	AstraZeneca	Phase 1/2	41
AZD9291 80mg oral each day	AstraZeneca	Phase 3	77
Tremelimumab + Durvalumab	AstraZeneca	Phase 2	52
Osimertinib	AstraZeneca	Phase 2	52
AZD3759 + AZD9291	AstraZeneca	Phase 1	33

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved